Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR

Takuya Tsuchihashi, Shuntaro Kagiyama, Kiyoshi Matsumura, Isao Abe, Masatoshi Fujishima

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.

Original languageEnglish
Pages (from-to)917-922
Number of pages6
JournalJournal of Hypertension
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 21 1999

Fingerprint

Inbred SHR Rats
Angiotensin II
Inbred WKY Rats
Brain Stem
Angiotensin II Type 1 Receptor Blockers
Peptidyl-Dipeptidase A
Renin-Angiotensin System
imidapril
candesartan cilexetil
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. / Tsuchihashi, Takuya; Kagiyama, Shuntaro; Matsumura, Kiyoshi; Abe, Isao; Fujishima, Masatoshi.

In: Journal of Hypertension, Vol. 17, No. 7, 21.07.1999, p. 917-922.

Research output: Contribution to journalArticle

Tsuchihashi, Takuya ; Kagiyama, Shuntaro ; Matsumura, Kiyoshi ; Abe, Isao ; Fujishima, Masatoshi. / Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. In: Journal of Hypertension. 1999 ; Vol. 17, No. 7. pp. 917-922.
@article{b1de2f15aa2442d8955bc86cb18757a8,
title = "Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR",
abstract = "Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.",
author = "Takuya Tsuchihashi and Shuntaro Kagiyama and Kiyoshi Matsumura and Isao Abe and Masatoshi Fujishima",
year = "1999",
month = "7",
day = "21",
doi = "10.1097/00004872-199917070-00007",
language = "English",
volume = "17",
pages = "917--922",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR

AU - Tsuchihashi, Takuya

AU - Kagiyama, Shuntaro

AU - Matsumura, Kiyoshi

AU - Abe, Isao

AU - Fujishima, Masatoshi

PY - 1999/7/21

Y1 - 1999/7/21

N2 - Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.

AB - Objective. To examine whether chronic oral treatment with an angiotensin-converting enzyme inhibitor imidapril and an angiotensin II type 1 receptor antagonist TCV-116 would alter the response to angiotensin II in the rostral ventrolateral medulla. Methods. Twelve-week-old spontaneously hypertensive rats (SHR) were treated with imidapril (20 mg/kg per day, n = 7), TCV-I16 (5 mg/kg per day, n = 8) or vehicle (n = 8) for 4 weeks. Wistar-Kyoto rats (WKY) (n = 8) served as normotensive controls. At 16 weeks of age, angiotensin II (100 pmol) was microinjected into the rostral ventrolateral medulla of anaesthetized rats. Results. Blood pressure decreased significantly in the rats treated with either imidapril or TCV-116. Presser responses to angiotensin II microinjected into the rostral ventrolateral medulla were comparable in the untreated SHR, the imidapril-treated SHR and WKY (12 ± 2, 15 ± 4 and 10 ± 1 mmHg, respectively), but were abolished in SHR treated with TCV-116 (0 ± 2 mmHg, P < 0.01). Angiotensin-converting enzyme activity in the brain stem was significantly lower in SHR treated with imidapril (0.70 ± 0.06 nmol/mg per h), but significantly higher in SHR treated with TCV-116 (1.62 ± 0.04 nmol/mg per h) than in the untreated SHR (1.37 ± 0.05 nmol/mg per h). Conclusions. Chronic oral treatment with imidapril and TCV-116 may have divergent influences on the renin-angiotensin system within the brain stem. TCV-116, but not imidapril, abolishes the presser effect of angiotensin II in the rostral ventrolateral medulla.

UR - http://www.scopus.com/inward/record.url?scp=0033024799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033024799&partnerID=8YFLogxK

U2 - 10.1097/00004872-199917070-00007

DO - 10.1097/00004872-199917070-00007

M3 - Article

VL - 17

SP - 917

EP - 922

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 7

ER -